Europe Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Embolic Agent and Support Device), Disease Indication (Cancer, Peripheral Vascular Disease, Neurological Disease, Urological and Nephrological Disorder, Gas

Europe Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Embolic Agent and Support Device), Disease Indication (Cancer, Peripheral Vascular Disease, Neurological Disease, Urological and Nephrological Disorder, Gastrointestinal Disorder, and Other), Procedure [Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), and Transarterial Chemoembolization (TACE)], and End User (Hospital & Clinic, Ambulatory Surgery Center, and Other End User)

The embolotherapy market in Europe is expected to grow from US$ 1,050.81 million in 2022 to US$ 1,638.92 million by 2028. It is estimated to grow at a CAGR of 7.7% from 2022 to 2028.

Rising Prevalence of Cancer Drives Growth of Embolotherapy Market in Europe

The five most common types of cancer are breast cancer, prostate cancer, cervical cancer, lung cancer, and colorectal cancer. Among these five cancer types, the leading cause of cancer-related death is lung cancer. Even though breast cancer has at least a 25% higher incidence among women, cervical carcinoma was the leading cause of death in 2020. In Denmark, the highest cancer rate for men and women combined was 334.9 people per 100,000. The age-standardized rate was at least 300 per 100,000 for ten countries—Denmark, Hungary, Ireland, Belgium, France, Australia, the Netherlands, Norway, France (New Caledonia), and Slovenia. In 2018, an estimated 233,000 women and 265,000 men in Germany were newly diagnosed with cancer. The total number of new cases per year has stagnated at around 500,000 for about ten years. Embolization is used to stop bleeding or block blood flow to a tumor or abnormal tissue area. It is also used to treat liver and kidney cancer and neuroendocrine tumors. Embolizing agents, including embolic microspheres (beads), are used to restrict the vascular supply of tumors and can be loaded with chemotherapeutic medicines, which elute and diffuse into the tissue. The vascular embolization device (previously the arterial embolization device) is intended to control hemorrhaging due to aneurysms, certain tumor types, and arteriovenous malformations. The pipeline embolization device is used for the treatment of large and giant wide-neck intracranial aneurysms in the internal carotid artery. It helps prevent aneurysms and tumors from growing and causing harm to essential organs. Thus, the rising prevalence of cancer cases is creating a high demand for embolotherapy products.

Market Overview



The embolotherapy market in Europe is segmented into Germany, France, the UK, Italy, Spain, and the rest of Europe. The market growth in the region is attributed to the increasing prevalence of cancers and brain aneurysms; rising preference for minimally invasive procedures; and surging investments, funds, and grants by public–private organizations for research. However, a dearth of skilled surgeons restrains the market growth. Germany is one of the significantly developed economies in Europe. Healthcare expenditure is increasing in Germany. Germany's spending on healthcare is higher (11% of its wealth) than the other countries spend (9.8% in the UK). The country has more doctors and hospital beds per patient than the UK. As per the data published in “The Burden of Stroke in Europe” report conducted by King’s College London for the Stroke Alliance for Europe, the number of stroke cases is around 88,922, which is 51.7 strokes per 100,000 inhabitants annually in Germany. The prevalence of stroke in Germany was around 526,774, accounting for 338.5 strokes per 100,000 inhabitants. The country also has a significant mortality rate of stroke, i.e., 75,861 deaths due to stroke per year. The incidence of strokes in Germany is estimated to increase by 30% by 2035. Also, the prevalence and mortality rates are expected to rise to 19% and 40%, respectively, by 2035.

Europe Embolotherapy Market Revenue and Forecast to 2028 (US$ Million)

Europe Embolotherapy Market Segmentation

The Europe embolotherapy market is segmented into product, disease indication, procedure, end user, and country.

Based on product, the market is segmented into embolic agents and support devices. The embolic agents segment registered the largest market share in 2022. Based on disease indication, the market is categorized into cancer, neurological diseases, urological and nephrological disorders, peripheral vascular diseases, gastrointestinal disorders, and others. The cancer segment held the largest market share in 2022. Based on procedure, the Europe embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization/selective internal radiation therapy, and transarterial chemoembolization (TACE). The transcatheter arterial embolization (TAE) segment held the largest market share in 2022. Based on end user, the Europe embolotherapy market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment held the largest market share in 2022. Based on country, the market is segmented into Germany, France, the UK, Italy, Spain, and Rest of Europe. Germany dominated the market share in 2022. Abbott Laboratories; Boston Scientific Corporation; Cook Medical LLC; Johnson & Johnson; Medtronic; Acandis GmbH; Balt USA LLC; Stryker Corporation; Guerbet LLC; and Terumo Corporation are the leading companies operating in the embolotherapy market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe embolotherapy market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe embolotherapy market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the embolotherapy market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution